Use of enteric-coated mycophenolate sodium in liver transplant patients with intestinal intolerance caused by mycophenolate mofetil

Clinical Transplantation

Volumn 23, Issue 6, 2009, Pages 882-886

  Doria, Cataldo ^a   Ramirez, Carlo B ^a   Frank, Adam M ^a   Vaccino, Silvia ^a   Fraser, Natalie ^a   Marino, Ignazio R ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Immunosuppression; Liver transplantation; Quality of life

Indexed keywords

CORTICOSTEROID; CYCLOSPORIN; METHYLPREDNISOLONE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; STEROID; TACROLIMUS; ENTERIC COATED TABLET; IMMUNOSUPPRESSIVE AGENT;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ENTERIC COATED TABLET; FEMALE; GASTROINTESTINAL SYMPTOM; GRAFT RECIPIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; LIVER TRANSPLANTATION; MALE; NEUTROPENIA; PILOT STUDY; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; QUALITY OF LIFE; QUALITY OF LIFE INDEX; ADOLESCENT; ANALOGS AND DERIVATIVES; CHEMICALLY INDUCED; COMPARATIVE STUDY; DOSE RESPONSE; DRUG TOLERANCE; FOLLOW UP; GASTROINTESTINAL DISEASES; GRAFT REJECTION; MIDDLE AGED; PROSPECTIVE STUDY; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG TOLERANCE; FEMALE; FOLLOW-UP STUDIES; GASTROINTESTINAL DISEASES; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; PILOT PROJECTS; PROSPECTIVE STUDIES; QUALITY OF LIFE; TABLETS, ENTERIC-COATED; TREATMENT OUTCOME; YOUNG ADULT;

EID: 71149097658     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/j.1399-0012.2009.01019.x     Document Type: Article

References (12)

1. Halloran PF. Molecular mechanisms of new immunosuppresants. Clin Transplant 1996, 9:118.
2. Salvadori M, Holzer H, de Mattos A. Enteric-coated mycophenolate sodium is therapeutically equivalent to mycophenolate mofetil in de novo renal transplant patients. Am J Transplant 2004, 4:231.
3. Budde K, Curtis J, Knoll G. Enteric-coated mycophenolate sodium can be safely administered in maintenance renal transplant patients: result of a 1 yr study. Am J Transplant 2004, 4:237.
4. Knoll GA, MacDonald I, Khan A, Van Walraven C. Mycophenolate mofetil dose reduction and the risk of acute rejection after renal transplantation. J Am Soc Nephrol 2003, 14:2381.
5. Hardinger KL, Brennan DC, Lowell J, Schnitzler MA. Long-term outcome of gastrointestinal complications in renal transplant patients treated with mycophenolate mofetil. Transpl Int 2004, 17:609.
6. Chan L, Mulgaonkar S, Walker R, Arns W, Ambuhl P, Schiavelli R. Patient-reported gastrointestinal symptom burden and health-related quality of life following conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium. Transplantation 2006, 81:1290.
7. Behrend M. Adverse gastrointestinal effects of mycophenolate mofetil: etiology, incidence and management. Drug Saf 2001, 24:645.
8. Ginsburg PM, Thuluvath PJ. Diarrhea in liver transplant recipients: etiology and management. Liver Transpl 2005, 11:881.
9. Eypasch E, Williams JI, Wood-Dauphinee S. Gastrointestinal Quality of Life Index: development, validation and application of a new instrument. Br J Surg. 1995, 82:216-22.
10. Kleinman L, Kilburg A, Machnicki G. Using GI-specific patient outcome measures in renal transplant patients: validation of the GSRS and GIQLI. Qual Life Res 2006, 15:1223.
11. Dumortier J, Gagnieu MC, Salandre J. Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in liver transplant patients presenting gastrointestinal disorders: a pilot study. Liver Transpl 2006, 12:1342.
12. Arns W. Noninfectious gastrointestinal (GI) complications of mycophenolic acid therapy: a consequence of local GI toxicity?. Transplant Proc 2007, 39:88.